Program
cobimetinib
Also written as “Cobimetinib”, “HM95573, cobimetinib” and “GDC-0973 IV Infusion”.
Its studies are mostly in Melanoma · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Neoplasms · Ovarian Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 364 open or running | phase 3since Sep 18, 2012 | Apr 18, 2007 | Nov 30, 2026phase 2 · NCT04302025 |
| Hanmi Pharmaceutical | 22 open or running | phase 2since Feb 27, 2026 | Aug 7, 2017 | Sep 2029phase 2 · NCT07449754 |
Also a collaborator on its studies: Halozyme Therapeutics and biolinerx-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 24 studies since Apr 18, 2007.
- Jun 5, 2017Phase 3 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT03178552 · 1,000 enrolled · United States, Argentina, Australia and more
- Jun 9, 2017Phase 2 study in Pancreatic AdenocarcinomaHoffmann-La Roche · NCT03193190 · 341 enrolled · United States, Germany, Japan and more
- Aug 7, 2017Hanmi Pharmaceutical's first study: phase 1 study in Neoplasm MetastasisNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT03284502 · 148 enrolled · Korea, Republic of
- Aug 17, 2017Phase 2 study in Solid TumorsHoffmann-La Roche · NCT03264066 · 87 enrolled · United States, Belgium, Germany and more
- Sep 1, 2017Phase 3 study in Advanced BRAFV600 Wild-type MelanomaHoffmann-La Roche · NCT03273153 · 446 enrolled · United States, Australia, Belgium and more
- Sep 11, 2017Phase 2 study in Esophageal NeoplasmsHoffmann-La Roche · NCT03281369 · 219 enrolled · United States, Australia, Israel and more
- Oct 12, 2017Phase 2 study in Multiple MyelomaHoffmann-La Roche · NCT03312530 · 49 enrolled · Czechia, Denmark, France and more
- Nov 7, 2017Phase 2 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT03337698 · 314 enrolled · United States, Australia, France and more
- Aug 2, 2018Phase 2 study in MelanomaHoffmann-La Roche · NCT03625141 · 80 enrolled · Brazil, France, Germany and more
- Sep 30, 2018Phase 1 study in Ovarian NeoplasmsHoffmann-La Roche · NCT03695380 · 77 enrolled · United States, Italy, Spain
- Mar 6, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT04302025 · 99 enrolled · United States
- Apr 6, 2021Phase 1 study in MelanomaHoffmann-La Roche · NCT04835805 · 65 enrolled · United States, Australia, Canada and more
- Jun 9, 2021Phase 2 study in Ovarian NeoplasmsHoffmann-La Roche · NCT04931342 · 176 enrolled · United States, Australia, Canada and more
- Feb 27, 2026Phase 2 study in MelanomaPhase 2 reachedHanmi Pharmaceutical · NCT07449754 · 45 planned · South Korea
Ahead
- Nov 30, 2026Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT04302025
- Dec 31, 2026Primary completion: phase 1 study in MelanomaHoffmann-La Roche · NCT04835805
- Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT03178552
- Feb 28, 2028Primary completion: phase 2 study in Ovarian NeoplasmsHoffmann-La Roche · NCT04931342
TargetBeta
“Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pimasertibrule | Merck KGaA, Darmstadt, Germany | phase 2 | 13 |
| mirdametinibrule | Merck KGaA, Darmstadt, Germany | phase 2 | 9 |
| polfurmetinib | Pfizer | phase 1 | 3 |
Studies
All 38 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07449754Melanoma · South Korea | 2 | Recruiting | Hanmi Pharmaceutical | Sep 2029 | 45 |
| NCT04931342Ovarian Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | Hoffmann-La Roche | Feb 28, 2028 | 176 |
| NCT04835805Melanoma · United States, Australia, Canada and more | 1 | Active, not recruiting | Hoffmann-La Roche | Dec 31, 2026 | 65 |
| NCT04302025Carcinoma, Non-Small-Cell Lung · United States | 2 | Active, not recruiting | Hoffmann-La Roche | Nov 30, 2026 | 99 |
| NCT03695380Ovarian Neoplasms · United States, Italy, Spain | 1 | Completed | Hoffmann-La Roche | Jul 12, 2023 | 77 |
| NCT03625141Melanoma · Brazil, France, Germany and more | 2 | Completed | Hoffmann-La Roche | Jun 7, 2021 | 80 |
| NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 2 | Terminated | Hoffmann-La Roche | Oct 14, 2025 | 314 |
| NCT03312530Multiple Myeloma · Czechia, Denmark, France and more | 2 | Completed | Hoffmann-La Roche | May 18, 2021 | 49 |
| NCT03281369Esophageal Neoplasms · United States, Australia, Israel and more | 2 | Terminated | Hoffmann-La Roche | Oct 9, 2025 | 219 |
| NCT03273153Advanced BRAFV600 Wild-type Melanoma · United States, Australia, Belgium and more | 3 | Terminated | Hoffmann-La Roche | Apr 15, 2019 | 446 |
| NCT03264066Solid Tumors · United States, Belgium, Germany and more | 2 | Completed | Hoffmann-La Roche | Jun 25, 2020 | 87 |
| NCT03284502Neoplasm Metastasis · Korea, Republic of | 1 | Active, not recruiting | Hanmi Pharmaceutical | Sep 30, 2024 | 148 |
| NCT03193190Pancreatic Adenocarcinoma · United States, Germany, Japan and more | 2 | Completed | Hoffmann-La Roche | Feb 27, 2025 | 341 |
| NCT03178552Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Hoffmann-La Roche | Jun 30, 2027 | 1,000 |
| NCT03178851Melanoma · United States, Australia, Bosnia and Herzegovina and more | 1 | Completed | Hoffmann-La Roche | May 29, 2019 | 155 |
| NCT02876224Colorectal Neoplasms · United States, Spain | 1 | Completed | Hoffmann-La Roche | Jun 25, 2019 | 51 |
| NCT02788279Colorectal Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Hoffmann-La Roche | Mar 9, 2018 | 363 |
| NCT02670044Leukemia, Myeloid, Acute · United States, Canada, France and more | 1 | Completed | Hoffmann-La Roche | Dec 10, 2020 | 88 |
| NCT02639546Solid Tumors · United States, France, Germany and more | 2 | Completed | Hoffmann-La Roche | Jul 21, 2021 | 56 |
| NCT02457793Carcinoma, Non-Small-Cell Lung · United States | 1 | Completed | Hoffmann-La Roche | Dec 5, 2016 | 24 |
| NCT02322814Breast Neoplasms · United States, Australia, Belgium and more | 2 | Terminated | Hoffmann-La Roche | Aug 10, 2018 | 169 |
| NCT02300025Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Jan 2015 | 28 |
| NCT02291289Colorectal Neoplasms · Argentina, Belgium, Bosnia and Herzegovina and more | 2 | Completed | Hoffmann-La Roche | May 31, 2019 | 1,044 |
| NCT02136524Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | May 2014 | 28 |
| NCT02091141Neoplasms · United States | 2 | Completed | Hoffmann-La Roche | May 24, 2023 | 673 |
| NCT01988896Solid Tumors · United States, Australia, Canada and more | 1 | Completed | Hoffmann-La Roche | Nov 4, 2019 | 153 |
| NCT01986166Neoplasms · United States, Spain | 1 | Completed | Hoffmann-La Roche | Jan 2016 | 23 |
| NCT01974258Neoplasms · United States | 1 | Withdrawn | Hoffmann-La Roche | Jul 2014 | 0 |
| NCT01929876Healthy Participants · United States | 1 | Completed | Hoffmann-La Roche | Oct 2013 | 16 |
| NCT01711762Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Sep 2012 | 6 |
| NCT01689519Melanoma · United States, Australia, Austria and more | 3 | Completed | Hoffmann-La Roche | May 9, 2014 | 495 |
| NCT01562275Neoplasms · United States, Spain | 1 | Completed | Hoffmann-La Roche | Jan 2015 | 67 |
| NCT01277718Healthy Volunteer | 1 | Completed | Hoffmann-La Roche | Feb 2011 | 20 |
| NCT01271803Melanoma · United States, Australia | 1 | Completed | Hoffmann-La Roche | Oct 1, 2013 | 131 |
| NCT01249131Healthy Volunteers | 1 | Completed | Hoffmann-La Roche | Jan 10, 2011 | 20 |
| NCT01249118Healthy Volunteers | 1 | Completed | Hoffmann-La Roche | Jan 2011 | 13 |
| NCT00996892Hereditary Sensory and Autonomic Neuropathies · United States | 1 | Terminated | Hoffmann-La Roche | Mar 2014 | 178 |
| NCT00467779Solid Tumor · United States | 1 | Completed | Hoffmann-La Roche | Apr 2014 | 119 |
How it is read
Names in the registry
- “Cobimetinib”, 34 entries
- “cobimetinib”, 4 entries
- “HM95573, cobimetinib”, 2 entries
- “GDC-0973 IV Infusion”, 1 entry
- “GDC-0973 Oral Capsules”, 1 entry
Conditions, from the studies’ own filings
- Melanoma, 7 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Colorectal Neoplasms, 3 studies
- Neoplasms, 3 studies
- Ovarian Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.